GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (WBO:AZNA) » Definitions » Cyclically Adjusted PB Ratio

AstraZeneca (WBO:AZNA) Cyclically Adjusted PB Ratio : 9.54 (As of Jun. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PB Ratio?

As of today (2024-06-04), AstraZeneca's current share price is €73.00. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €7.65. AstraZeneca's Cyclically Adjusted PB Ratio for today is 9.54.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:AZNA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.78   Med: 5.62   Max: 10.1
Current: 9.37

During the past years, AstraZeneca's highest Cyclically Adjusted PB Ratio was 10.10. The lowest was 3.78. And the median was 5.62.

WBO:AZNA's Cyclically Adjusted PB Ratio is ranked worse than
92.27% of 724 companies
in the Drug Manufacturers industry
Industry Median: 1.875 vs WBO:AZNA: 9.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's adjusted book value per share data for the three months ended in Mar. 2024 was €11.111. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7.65 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 7.32 8.24 9.33 8.20

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 8.95 8.70 8.20 8.11

Competitive Comparison of AstraZeneca's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.



AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=73.00/7.65
=9.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.111/131.6000*131.6000
=11.111

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201406 6.419 99.800 8.464
201409 6.281 100.000 8.266
201412 6.301 99.900 8.300
201503 6.190 99.600 8.179
201506 6.444 100.100 8.472
201509 6.115 100.200 8.031
201512 6.714 100.400 8.800
201603 5.232 100.400 6.858
201606 4.760 101.000 6.202
201609 4.604 101.500 5.969
201612 5.565 102.200 7.166
201703 4.796 102.700 6.146
201706 4.800 103.500 6.103
201709 4.548 104.300 5.738
201712 4.992 105.000 6.257
201803 4.135 105.100 5.178
201806 4.273 105.900 5.310
201809 4.037 106.600 4.984
201812 4.325 107.100 5.314
201903 3.536 107.000 4.349
201906 4.570 107.900 5.574
201909 4.210 108.400 5.111
201912 4.502 108.500 5.460
202003 3.717 108.600 4.504
202006 4.140 108.800 5.008
202009 3.945 109.200 4.754
202012 4.891 109.400 5.884
202103 4.617 109.700 5.539
202106 4.956 111.400 5.855
202109 10.904 112.400 12.767
202112 11.215 114.700 12.867
202203 10.648 116.500 12.028
202206 10.969 120.500 11.979
202209 11.451 122.300 12.322
202212 11.280 125.300 11.847
202303 10.784 126.800 11.192
202306 11.134 129.400 11.323
202309 11.244 130.100 11.374
202312 11.578 130.500 11.676
202403 11.111 131.600 11.111

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (WBO:AZNA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (WBO:AZNA) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (WBO:AZNA) Headlines

No Headlines